67.40
+3.06%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharma Mar
Its shares trade on BME under the ticker PHM.MC. It has been listed since 2 November 2015. In the fiscal year to 31 December 2025, it reported revenue of €221.4m and net income of €75.0m. At that date it held total assets of €395.1m and shareholders' equity of €251.8m.
Pharma Mar SA is a biopharmaceutical holding company, which engages in discovery and development of innovative marine-derived anticancer drugs. The company is headquartered in Colmenar Viejo, Madrid. The company went IPO on 2015-11-02. The firm focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. The company manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The firm operates through subsidiaries in Italy, Germany, France, and the United States, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Nov 2015
- Employees
- 443
- Website
- pharmamar.com/es ↗
Leadership
Pay as last reported
- Mr. Jose Maria Fernandez Sousa-FaroExecutive Chairman of the Board, since 2023€3.2m
- Mr. Pedro Francisco Fernandez PuentesExecutive Vice Chairman of the Board€573,000
- Ms. Maria Luisa de Francia CaballeroChief Financial Officer
- Ms. Sandra Llamera SanchezGlobal Chief Compliance Officer
- Ms. Maria Concepcion Sanz LopezGeneral Counsel to Business
- Mr. Luis Mora CapitanGeneral Manager - Oncology Business Unit, since 2024
- Mr. Jose Luis Moreno Martinez-LosaDirector - Investor Relations and Capital Markets
- Ms. Ines Perez CallejaDirector - Quality Unit
- Mr. Juan Carlos Villalon GomezInternal Auditor
- Mr. Juan Gomez PulidoSecretary General, Non-Member Secretary of the Board
- Mr. Mariano Esteban RodriguezLead Independent Director€115,000
- Ms. Montserrat Andrade DetrellProprietary Director€273,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 99
- Social
- 99
- Governance
- 28
- Direct emissions (scope 1)
- 1,233 t
- Energy emissions (scope 2)
- 1,359 t
- Value chain emissions (scope 3)
- 15,876 t
- Women in the workforce
- 61.5%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharma Mar SA possess several strengths that contribute to its success in the pharmaceutical industry. These strengths include:
- Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:
- There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:
- Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:
Weaknesses
- Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:
- There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:
- Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:
Opportunities
- There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:
- Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:
Threats
- Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.